Boston Scientific Corporation announces the completion of the first US procedures performed with the Symphion System, designed for the hysteroscopic removal of interuterine fibroids and polyps. The all-in-one Symphion System combines a self-contained, recirculating fluid management system, direct intrauterine pressure monitoring and bladeless bipolar RF plasma resection to remove uterine tissue. Hysteroscopic removal of symptomatic fibroids and polyps is a minimally invasive surgical technique and intended to be less traumatic to the patient.   

"The Symphion System limits the amount of fluid that can be absorbed by the patient and provides excellent visualisation with internal pressure monitoring and spot coagulation," said Dr. Amy Garcia, director of Minimally Invasive Gynaecology at the Center for Women's Surgery in Albuquerque, New Mexico. "These features, coupled with bipolar resection, are game changers that greatly benefit both the clinician and the patient," said Dr. Garcia.

Fibroids and polyps, which affect an estimated two million women in the US per year, are uterine growths that are symptomatic approximately 25 per cent  of the time and can cause pain, cramping, incontinence, constipation, excessive bleeding, and infertility. Hysteroscopic removal involves inserting specialized tools transcervically into the uterus under direct visualisation to remove targeted tissue.

"The Symphion System expands our women's health portfolio into hysteroscopy, an important treatment option for women suffering from the symptoms associated with fibroids and polyps," said Karen Prange, president of Urology and Women's Health at Boston Scientific. "The successful completion of these first cases in the US demonstrates the potential for this novel technology to improve the lives of patients."

Boston Scientific will introduce the system during the American Association of Gynaecologic Laparoscopists (AAGL) 43rd Global Congress to be held in Vancouver, British Columbia, November 17th through the 21st.